Dr. Vicki L Chenarides, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 857 Route 82, Hopewell Jct, NY 12533 Phone: 845-227-2233 |
News Archive
YM BioSciences Inc. today announced positive interim data from the first 60 patients enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. The results were reported today in an oral presentation at the 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida.
Syneron Medical Ltd., the global leader in medical aesthetic products and technology, announced today that it has received United States Food and Drug Administration (FDA) clearance for elos Plus, a next generation multi-platform system featuring the Company's proprietary elos technology.
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
With unprecedented demographic trends leading to an aging workforce, a new emphasis on productive aging is needed to keep US workers of all generations as healthy and productive as possible, according to an article in the May Journal of Occupational and Environmental Medicine.
› Verified 3 days ago